Dossier
bowel disease drug trial
Coverage of bowel disease drug trial in the Nexus archive.
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax fell 32% following updated trial data on its lead asset for bowel disease. The stock decline occurred after the company reported fresh data on its primary drug candidate.